Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Laquinimod - Active Biotech

Drug Profile

Laquinimod - Active Biotech

Alternative Names: ABR-215062; Laquinimod sodium; Nerventra; SAIK-MS; TV-5600

Latest Information Update: 03 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Icahn School of Medicine at Mount Sinai; National University of Singapore; Ruhr-University Bochum; Tel Aviv University; University College London; University of British Columbia
  • Class Amides; Anti-inflammatories; Chlorinated hydrocarbons; Eye disorder therapies; Neuropsychotherapeutics; Quinolones; Small molecules; Urologics
  • Mechanism of Action Aryl hydrocarbon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Uveitis

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase I Uveitis
  • Preclinical Wet age-related macular degeneration
  • Suspended Crohn's disease
  • Discontinued Huntington's disease; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 22 Dec 2023 Global Ophthalmic Research Center plans a phase I LION study of laquinimod for the treatment of Uveitis in Q1 2024 (Ophthalmic, Drops) (NCT06161415)
  • 05 Dec 2023 Active Biotech and the Global Ophthalmic Research Center (GORC) entered into a clinical trial collaboration agreement for the treatment of Uveitis
  • 30 Jan 2023 Adverse events data from a phase I trial in Uveitis released by Active Biotech
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top